Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Influenza

  Free Subscription


Articles published in Cell

Retrieve available abstracts of 159 articles:
HTML format



Single Articles


    September 2021
  1. ZIEGLER CGK, Miao VN, Owings AH, Navia AW, et al
    Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
    Cell. 2021;184:4713-4733.
    PubMed     Abstract available


    August 2021
  2. KARLSSON EA, Duong V
    The continuing search for the origins of SARS-CoV-2.
    Cell. 2021;184:4373-4374.
    PubMed     Abstract available


  3. KANG L, He G, Sharp AK, Wang X, et al
    A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation.
    Cell. 2021;184:4392-4400.
    PubMed     Abstract available


  4. NATHAN A, Rossin EJ, Kaseke C, Park RJ, et al
    Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Cell. 2021;184:4401-4413.
    PubMed     Abstract available


  5. ZHOU H, Ji J, Chen X, Bi Y, et al
    Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses.
    Cell. 2021;184:4380-4391.
    PubMed     Abstract available


  6. LIU C, Ginn HM, Dejnirattisai W, Supasa P, et al
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Cell. 2021;184:4220-4236.
    PubMed     Abstract available


  7. LI D, Edwards RJ, Manne K, Martinez DR, et al
    In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
    Cell. 2021;184:4203-4219.
    PubMed     Abstract available


    July 2021
  8. RESCIGNO M
    Unraveling the long-term effect of influenza vaccines.
    Cell. 2021;184:3845-3847.
    PubMed     Abstract available


  9. WEINGARTEN-GABBAY S, Klaeger S, Sarkizova S, Pearlman LR, et al
    Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Cell. 2021;184:3962-3980.
    PubMed     Abstract available


  10. COPIN R, Baum A, Wloga E, Pascal KE, et al
    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
    Cell. 2021;184:3949-3961.
    PubMed     Abstract available


    June 2021
  11. YAN L, Yang Y, Li M, Zhang Y, et al
    Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.
    Cell. 2021;184:3474-3485.
    PubMed     Abstract available


  12. LIU K, Pan X, Li L, Yu F, et al
    Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
    Cell. 2021;184:3438-3451.
    PubMed     Abstract available


  13. LIU Y, Soh WT, Kishikawa JI, Hirose M, et al
    An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
    Cell. 2021;184:3452-3466.
    PubMed     Abstract available


  14. HE X, Chandrashekar A, Zahn R, Wegmann F, et al
    Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    Cell. 2021;184:3467-3473.
    PubMed     Abstract available


  15. HAO Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al
    Integrated analysis of multimodal single-cell data.
    Cell. 2021;184:3573-3587.
    PubMed     Abstract available


  16. DENG X, Garcia-Knight MA, Khalid MM, Servellita V, et al
    Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
    Cell. 2021;184:3426-3437.
    PubMed     Abstract available


  17. WIMMERS F, Donato M, Kuo A, Ashuach T, et al
    The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.
    Cell. 2021 Jun 22. pii: S0092-8674(21)00692-9. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  18. CORTI D, Purcell LA, Snell G, Veesler D, et al
    Tackling COVID-19 with neutralizing monoclonal antibodies.
    Cell. 2021;184:3086-3108.
    PubMed     Abstract available


  19. SCHEID JF, Barnes CO, Eraslan B, Hudak A, et al
    B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Cell. 2021;184:3205-3221.
    PubMed     Abstract available


  20. ASARNOW D, Wang B, Lee WH, Hu Y, et al
    Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Cell. 2021;184:3192-3204.
    PubMed     Abstract available


    May 2021
  21. BAUMER Y, Powell-Wiley TM
    Interdisciplinary approaches are fundamental to decode the biology of adversity.
    Cell. 2021;184:2797-2801.
    PubMed     Abstract available


  22. GARRETT ME, Galloway J, Chu HY, Itell HL, et al
    High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
    Cell. 2021;184:2927-2938.
    PubMed     Abstract available


  23. DEJNIRATTISAI W, Zhou D, Supasa P, Liu C, et al
    Antibody evasion by the P.1 strain of SARS-CoV-2.
    Cell. 2021;184:2939-2954.
    PubMed     Abstract available


  24. WILLIAMS WB, Meyerhoff RR, Edwards RJ, Li H, et al
    Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
    Cell. 2021 May 18. pii: S0092-8674(21)00577-8. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  25. ALPERT T, Brito AF, Lasek-Nesselquist E, Rothman J, et al
    Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
    Cell. 2021;184:2595-2604.
    PubMed     Abstract available


  26. WASHINGTON NL, Gangavarapu K, Zeller M, Bolze A, et al
    Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
    Cell. 2021;184:2587-2594.
    PubMed     Abstract available


  27. HO JSY, Mok BW, Campisi L, Jordan T, et al
    TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
    Cell. 2021;184:2618-2632.
    PubMed     Abstract available


  28. CLARK SA, Clark LE, Pan J, Coscia A, et al
    SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
    Cell. 2021;184:2605-2617.
    PubMed     Abstract available


    April 2021
  29. LEBLANC EV, Colpitts CC
    SARS-CoV-2 RNA: Exclusive friends and common foes.
    Cell. 2021;184:2276-2278.
    PubMed     Abstract available


  30. BOEHM JS
    The power of parent scientists.
    Cell. 2021;184:2263-2270.
    PubMed     Abstract available


  31. HOFFMANN M, Arora P, Gross R, Seidel A, et al
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Cell. 2021;184:2384-2393.
    PubMed     Abstract available


  32. SURYADEVARA N, Shrihari S, Gilchuk P, VanBlargan LA, et al
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
    Cell. 2021;184:2316-2331.
    PubMed     Abstract available


  33. FABIUS JM, Krogan NJ
    Creating collaboration by breaking down scientific barriers.
    Cell. 2021;184:2271-2275.
    PubMed     Abstract available


  34. MCCALLUM M, De Marco A, Lempp FA, Tortorici MA, et al
    N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
    Cell. 2021;184:2332-2347.
    PubMed     Abstract available


  35. GARCIA-BELTRAN WF, Lam EC, St Denis K, Nitido AD, et al
    Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Cell. 2021;184:2372-2383.
    PubMed     Abstract available


  36. FLYNN RA, Belk JA, Qi Y, Yasumoto Y, et al
    Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.
    Cell. 2021;184:2394-2411.
    PubMed     Abstract available


  37. ZHOU D, Dejnirattisai W, Supasa P, Liu C, et al
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
    Cell. 2021;184:2348-2361.
    PubMed     Abstract available



  38. The origins of viral infection sleuth.
    Cell. 2021;184:1960-1961.
    PubMed     Abstract available


  39. SCHNEIDER JL, Rowe JH, Garcia-de-Alba C, Kim CF, et al
    The aging lung: Physiology, disease, and immunity.
    Cell. 2021;184:1990-2019.
    PubMed     Abstract available


  40. MILLS RJ, Humphrey SJ, Fortuna PRJ, Lor M, et al
    BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
    Cell. 2021;184:2167-2182.
    PubMed     Abstract available


  41. DEJNIRATTISAI W, Zhou D, Ginn HM, Duyvesteyn HME, et al
    The antigenic anatomy of SARS-CoV-2 receptor binding domain.
    Cell. 2021;184:2183-2200.
    PubMed     Abstract available


  42. SUPASA P, Zhou D, Dejnirattisai W, Liu C, et al
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
    Cell. 2021;184:2201-2211.
    PubMed     Abstract available


  43. YEUNG ML, Teng JLL, Jia L, Zhang C, et al
    Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
    Cell. 2021;184:2212-2228.
    PubMed     Abstract available


  44. ZHANG X, Liu Y, Liu J, Bailey AL, et al
    A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
    Cell. 2021;184:2229-2238.
    PubMed     Abstract available


  45. SCHULTZE JL, Aschenbrenner AC
    COVID-19 and the human innate immune system.
    Cell. 2021;184:1671-1692.
    PubMed     Abstract available


  46. YU B, Qi Y, Li R, Shi Q, et al
    B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells.
    Cell. 2021;184:1790-1803.
    PubMed     Abstract available


  47. LIU C, Martins AJ, Lau WW, Rachmaninoff N, et al
    Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.
    Cell. 2021;184:1836-1857.
    PubMed     Abstract available


  48. WINKLER ES, Gilchuk P, Yu J, Bailey AL, et al
    Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
    Cell. 2021;184:1804-1820.
    PubMed     Abstract available


  49. ANDREANO E, Nicastri E, Paciello I, Pileri P, et al
    Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
    Cell. 2021;184:1821-1835.
    PubMed     Abstract available


  50. REN X, Wen W, Fan X, Hou W, et al
    COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
    Cell. 2021;184:1895-1913.
    PubMed     Abstract available


  51. SUN L, Li P, Ju X, Rao J, et al
    In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
    Cell. 2021;184:1865-1883.
    PubMed     Abstract available


  52. ANDERSON EM, Goodwin EC, Verma A, Arevalo CP, et al
    Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
    Cell. 2021;184:1858-1864.
    PubMed     Abstract available


    March 2021
  53. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
    Novel approaches for vaccine development.
    Cell. 2021;184:1589-1603.
    PubMed     Abstract available


  54. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
    Active learning-based STEM education for in-person and online learning.
    Cell. 2021;184:1409-1414.
    PubMed     Abstract available



  55. Scientific misinformation: A perfect storm, missteps, and moving forward.
    Cell. 2021;184:1402-1406.
    PubMed     Abstract available


  56. TOPOL EJ
    Messenger RNA vaccines against SARS-CoV-2.
    Cell. 2021;184:1401.
    PubMed     Abstract available


  57. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
    Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
    Cell. 2021;184:1530-1544.
    PubMed     Abstract available


  58. MANN ME, Hall LJ, Dulvy NK
    Scientific impact in a changing world.
    Cell. 2021;184:1407-1408.
    PubMed     Abstract available


  59. THOMSON EC, Rosen LE, Shepherd JG, Spreafico R, et al
    Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
    Cell. 2021;184:1171-1187.
    PubMed     Abstract available


  60. GRUBAUGH ND, Hodcroft EB, Fauver JR, Phelan AL, et al
    Public health actions to control new SARS-CoV-2 variants.
    Cell. 2021;184:1127-1132.
    PubMed     Abstract available


  61. BROUWER PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al
    Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
    Cell. 2021;184:1188-1200.
    PubMed     Abstract available


  62. SOKAL A, Chappert P, Barba-Spaeth G, Roeser A, et al
    Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
    Cell. 2021;184:1201-1213.
    PubMed     Abstract available


    February 2021
  63. LI Q, Nie J, Wu J, Zhang L, et al
    SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
    Cell. 2021 Feb 23. pii: S0092-8674(21)00231-2. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available


  64. SETTE A, Crotty S
    Adaptive immunity to SARS-CoV-2 and COVID-19.
    Cell. 2021;184:861-880.
    PubMed     Abstract available


  65. NIE X, Qian L, Sun R, Huang B, et al
    Multi-organ proteomic landscape of COVID-19 autopsies.
    Cell. 2021;184:775-791.
    PubMed     Abstract available


  66. ATYEO C, Pullen KM, Bordt EA, Fischinger S, et al
    Compromised SARS-CoV-2-specific placental antibody transfer.
    Cell. 2021;184:628-642.
    PubMed     Abstract available


    January 2021
  67. GARCIA-BELTRAN WF, Lam EC, Astudillo MG, Yang D, et al
    COVID-19-neutralizing antibodies predict disease severity and survival.
    Cell. 2021;184:476-488.
    PubMed     Abstract available


  68. HOANG TN, Pino M, Boddapati AK, Viox EG, et al
    Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Cell. 2021;184:460-475.
    PubMed     Abstract available



  69. What happens next.
    Cell. 2021;184:291-292.
    PubMed    


  70. HOFFMANN HH, Schneider WM, Rozen-Gagnon K, Miles LA, et al
    TMEM41B Is a Pan-flavivirus Host Factor.
    Cell. 2021;184:133-148.
    PubMed     Abstract available


  71. WANG R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, et al
    Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
    Cell. 2021;184:106-119.
    PubMed     Abstract available


  72. RODDA LB, Netland J, Shehata L, Pruner KB, et al
    Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
    Cell. 2021;184:169-183.
    PubMed     Abstract available


  73. KARKI R, Sharma BR, Tuladhar S, Williams EP, et al
    Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.
    Cell. 2021;184:149-168.
    PubMed     Abstract available


  74. VOLZ E, Hill V, McCrone JT, Price A, et al
    Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
    Cell. 2021;184:64-75.
    PubMed     Abstract available


  75. DANILOSKI Z, Jordan TX, Wessels HH, Hoagland DA, et al
    Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
    Cell. 2021;184:92-105.
    PubMed     Abstract available


  76. WEI J, Alfajaro MM, DeWeirdt PC, Hanna RE, et al
    Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.
    Cell. 2021;184:76-91.
    PubMed     Abstract available


    December 2020
  77. AVANZATO VA, Matson MJ, Seifert SN, Pryce R, et al
    Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
    Cell. 2020;183:1901-1912.
    PubMed     Abstract available


  78. ZOHAR T, Loos C, Fischinger S, Atyeo C, et al
    Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
    Cell. 2020;183:1508-1519.
    PubMed     Abstract available


  79. SU Y, Chen D, Yuan D, Lausted C, et al
    Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
    Cell. 2020;183:1479-1495.
    PubMed     Abstract available


  80. CHEN Y, Zuiani A, Fischinger S, Mullur J, et al
    Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
    Cell. 2020;183:1496-1507.
    PubMed     Abstract available


  81. GHOSH S, Dellibovi-Ragheb TA, Kerviel A, Pak E, et al
    beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
    Cell. 2020;183:1520-1535.
    PubMed     Abstract available


    November 2020
  82. WALLS AC, Fiala B, Schafer A, Wrenn S, et al
    Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Cell. 2020;183:1367-1382.
    PubMed     Abstract available


  83. MECKIFF BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, et al
    Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.
    Cell. 2020;183:1340-1353.
    PubMed     Abstract available


  84. BANERJEE AK, Blanco MR, Bruce EA, Honson DD, et al
    SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.
    Cell. 2020;183:1325-1339.
    PubMed     Abstract available


  85. AID M, Busman-Sahay K, Vidal SJ, Maliga Z, et al
    Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.
    Cell. 2020;183:1354-1366.
    PubMed     Abstract available


  86. KREYE J, Reincke SM, Kornau HC, Sanchez-Sendin E, et al
    A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Cell. 2020;183:1058-1069.
    PubMed     Abstract available


  87. LEIST SR, Dinnon KH 3rd, Schafer A, Tse LV, et al
    A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
    Cell. 2020;183:1070-1085.
    PubMed     Abstract available


  88. RYDYZNSKI MODERBACHER C, Ramirez SI, Dan JM, Grifoni A, et al
    Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
    Cell. 2020;183:996-1012.
    PubMed     Abstract available


  89. PICCOLI L, Park YJ, Tortorici MA, Czudnochowski N, et al
    Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Cell. 2020;183:1024-1042.
    PubMed     Abstract available


  90. GRUBER CN, Patel RS, Trachtman R, Lepow L, et al
    Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
    Cell. 2020;183:982-995.
    PubMed     Abstract available


  91. CLAUSEN TM, Sandoval DR, Spliid CB, Pihl J, et al
    SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
    Cell. 2020;183:1043-1057.
    PubMed     Abstract available


  92. CONSIGLIO CR, Cotugno N, Sardh F, Pou C, et al
    The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
    Cell. 2020;183:968-981.
    PubMed     Abstract available


    October 2020
  93. YURKOVETSKIY L, Wang X, Pascal KE, Tomkins-Tinch C, et al
    Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
    Cell. 2020;183:739-751.
    PubMed     Abstract available


  94. MUKHERJEE S
    Before Virus, After Virus: A Reckoning.
    Cell. 2020;183:308-314.
    PubMed     Abstract available


  95. IWASAKI A, Omer SB
    Why and How Vaccines Work.
    Cell. 2020;183:290-295.
    PubMed     Abstract available


  96. GOLDSTEIN JL
    The Spanish 1918 Flu and the COVID-19 Disease: The Art of Remembering and Foreshadowing Pandemics.
    Cell. 2020;183:285-289.
    PubMed     Abstract available


  97. LI W, Schafer A, Kulkarni SS, Liu X, et al
    High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
    Cell. 2020;183:429-441.
    PubMed     Abstract available


  98. SEKINE T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, et al
    Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
    Cell. 2020;183:158-168.
    PubMed     Abstract available


  99. AU L, Boos LA, Swerdlow A, Byrne F, et al
    Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.
    Cell. 2020;183:4-10.
    PubMed     Abstract available


  100. CANETE PF, Vinuesa CG
    COVID-19 Makes B Cells Forget, but T Cells Remember.
    Cell. 2020;183:13-15.
    PubMed     Abstract available


  101. HASSAN AO, Kafai NM, Dmitriev IP, Fox JM, et al
    A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
    Cell. 2020;183:169-184.
    PubMed     Abstract available


  102. IADECOLA C, Anrather J, Kamel H
    Effects of COVID-19 on the Nervous System.
    Cell. 2020;183:16-27.
    PubMed     Abstract available


  103. KANEKO N, Kuo HH, Boucau J, Farmer JR, et al
    Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
    Cell. 2020;183:143-157.
    PubMed     Abstract available


    September 2020
  104. SILVIN A, Chapuis N, Dunsmore G, Goubet AG, et al
    Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
    Cell. 2020;182:1401-1418.
    PubMed     Abstract available


  105. COLUBRI A, Kemball M, Sani K, Boehm C, et al
    Preventing Outbreaks through Interactive, Experiential Real-Life Simulations.
    Cell. 2020;182:1366-1371.
    PubMed     Abstract available


  106. SCHULTE-SCHREPPING J, Reusch N, Paclik D, Bassler K, et al
    Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
    Cell. 2020;182:1419-1440.
    PubMed     Abstract available


  107. DU S, Cao Y, Zhu Q, Yu P, et al
    Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Cell. 2020 Sep 14. pii: S0092-8674(20)31232-0. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  108. MORENS DM, Fauci AS
    Emerging Pandemic Diseases: How We Got to COVID-19.
    Cell. 2020;182:1077-1092.
    PubMed     Abstract available


    August 2020
  109. GRUBAUGH ND, Hanage WP, Rasmussen AL
    Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear.
    Cell. 2020;182:794-795.
    PubMed     Abstract available


  110. KORBER B, Fischer WM, Gnanakaran S, Yoon H, et al
    Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
    Cell. 2020;182:812-827.
    PubMed     Abstract available


  111. KREER C, Zehner M, Weber T, Ercanoglu MS, et al
    Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
    Cell. 2020;182:843-854.
    PubMed     Abstract available


  112. BARNES CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, et al
    Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Cell. 2020;182:828-842.
    PubMed     Abstract available


  113. GEITMANN A
    Travel Less. Make It Worthwhile.
    Cell. 2020;182:790-793.
    PubMed     Abstract available


  114. WANG H, Zhang Y, Huang B, Deng W, et al
    Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Cell. 2020;182:713-721.
    PubMed     Abstract available


  115. DAI L, Zheng T, Xu K, Han Y, et al
    A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Cell. 2020;182:722-733.
    PubMed     Abstract available


  116. BOUHADDOU M, Memon D, Meyer B, White KM, et al
    The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
    Cell. 2020;182:685-712.
    PubMed     Abstract available


  117. SUN J, Zhuang Z, Zheng J, Li K, et al
    Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
    Cell. 2020;182:734-743.
    PubMed     Abstract available


  118. HASSAN AO, Case JB, Winkler ES, Thackray LB, et al
    A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
    Cell. 2020;182:744-753.
    PubMed     Abstract available


    July 2020
  119. EINAV T, Gentles LE, Bloom JD
    SnapShot: Influenza by the Numbers.
    Cell. 2020;182:532-532.
    PubMed     Abstract available


  120. JIANG RD, Liu MQ, Chen Y, Shan C, et al
    Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
    Cell. 2020;182:50-58.
    PubMed     Abstract available


  121. SHEN B, Yi X, Sun Y, Bi X, et al
    Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
    Cell. 2020;182:59-72.
    PubMed     Abstract available


  122. CAO Y, Su B, Guo X, Sun W, et al
    Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
    Cell. 2020;182:73-84.
    PubMed     Abstract available


  123. JOYCE MG, Wheatley AK, Modjarrad K
    Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
    Cell. 2020;182:7-9.
    PubMed     Abstract available


    June 2020
  124. SEMPOWSKI GD, Saunders KO, Acharya P, Wiehe KJ, et al
    Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
    Cell. 2020;181:1458-1463.
    PubMed     Abstract available


  125. BOST P, Giladi A, Liu Y, Bendjelal Y, et al
    Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.
    Cell. 2020;181:1475-1488.
    PubMed     Abstract available


  126. GRIFONI A, Weiskopf D, Ramirez SI, Mateus J, et al
    Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Cell. 2020;181:1489-1501.
    PubMed     Abstract available


  127. ZEGGINI E, Baumann M, Gotz M, Herzig S, et al
    Biomedical Research Goes Viral: Dangers and Opportunities.
    Cell. 2020;181:1189-1193.
    PubMed     Abstract available


  128. ZHANG K, Liu X, Shen J, Li Z, et al
    Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.
    Cell. 2020;181:1423-1433.
    PubMed     Abstract available


  129. CASANOVA JL, Su HC
    A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.
    Cell. 2020;181:1194-1199.
    PubMed     Abstract available


    May 2020
  130. NETEA MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, et al
    Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.
    Cell. 2020;181:969-977.
    PubMed     Abstract available


  131. BLANCO-MELO D, Nilsson-Payant BE, Liu WC, Uhl S, et al
    Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
    Cell. 2020;181:1036-1045.
    PubMed     Abstract available


  132. ZIEGLER CGK, Allon SJ, Nyquist SK, Mbano IM, et al
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
    Cell. 2020;181:1016-1035.
    PubMed     Abstract available


  133. FAUVER JR, Petrone ME, Hodcroft EB, Shioda K, et al
    Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.
    Cell. 2020;181:990-996.
    PubMed     Abstract available


  134. WRAPP D, De Vlieger D, Corbett KS, Torres GM, et al
    Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
    Cell. 2020;181:1004-1015.
    PubMed     Abstract available


  135. LU J, du Plessis L, Liu Z, Hill V, et al
    Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
    Cell. 2020;181:997-1003.
    PubMed     Abstract available


  136. HOU YJ, Okuda K, Edwards CE, Martinez DR, et al
    SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
    Cell. 2020 May 27. pii: S0092-8674(20)30675-9. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  137. OBERFELD B, Achanta A, Carpenter K, Chen P, et al
    SnapShot: COVID-19.
    Cell. 2020;181:954-954.
    PubMed     Abstract available


  138. MONTEIL V, Kwon H, Prado P, Hagelkruys A, et al
    Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
    Cell. 2020;181:905-913.
    PubMed     Abstract available


    April 2020
  139. ABBOTT TR, Dhamdhere G, Liu Y, Lin X, et al
    Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
    Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available


  140. WANDZIK JM, Kouba T, Karuppasamy M, Pflug A, et al
    A Structure-Based Model for the Complete Transcription Cycle of Influenza Polymerase.
    Cell. 2020 Apr 16. pii: S0092-8674(20)30389-5. doi: 10.1016/j.cell.2020.
    PubMed     Abstract available



  141. COVID-19: Navigating Uncertainties Together.
    Cell. 2020;181:209-210.
    PubMed    


  142. ZHANG YZ, Holmes EC
    A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.
    Cell. 2020;181:223-227.
    PubMed     Abstract available


  143. HOFFMANN M, Kleine-Weber H, Schroeder S, Kruger N, et al
    SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Cell. 2020;181:271-280.
    PubMed     Abstract available


    March 2020
  144. ZHANG T, Yin C, Boyd DF, Quarato G, et al
    Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis.
    Cell. 2020;180:1115-1129.
    PubMed     Abstract available



  145. The Novel Coronavirus Outbreak: What We Know and What We Don't.
    Cell. 2020;180:1034-1036.
    PubMed    


    January 2020
  146. VAHEY MD, Fletcher DA
    Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
    Cell. 2020;180:205.
    PubMed    


    May 2019
  147. GARCIA-SASTRE A
    Snatch-and-Grab Inhibitors to Fight the Flu.
    Cell. 2019;177:1367.
    PubMed     Abstract available


  148. BANGARU S, Lang S, Schotsaert M, Vanderven HA, et al
    A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.
    Cell. 2019;177:1136-1152.
    PubMed     Abstract available


  149. WATANABE A, McCarthy KR, Kuraoka M, Schmidt AG, et al
    Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism.
    Cell. 2019;177:1124-1135.
    PubMed     Abstract available


  150. WU Y, Gao GF
    "Breathing" Hemagglutinin Reveals Cryptic Epitopes for Universal Influenza Vaccine Design.
    Cell. 2019;177:1086-1088.
    PubMed     Abstract available


    January 2019
  151. VAHEY MD, Fletcher DA
    Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
    Cell. 2019;176:678.
    PubMed    


  152. MARTIN BE, Brooke CB
    Flu Shows the Power of Diversity.
    Cell. 2019;176.
    PubMed     Abstract available


    November 2018
  153. VAHEY MD, Fletcher DA
    Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
    Cell. 2018 Nov 27. pii: S0092-8674(18)31455-7. doi: 10.1016/j.cell.2018.
    PubMed     Abstract available


    June 2018
  154. DAS DK, Govindan R, Nikic-Spiegel I, Krammer F, et al
    Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers.
    Cell. 2018 Jun 21. pii: S0092-8674(18)30713-X. doi: 10.1016/j.cell.2018.
    PubMed     Abstract available


    April 2018
  155. CHEN YQ, Wohlbold TJ, Zheng NY, Huang M, et al
    Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
    Cell. 2018;173:417-429.
    PubMed     Abstract available


    March 2018
  156. GAO GF
    From "A"IV to "Z"IKV: Attacks from Emerging and Re-emerging Pathogens.
    Cell. 2018;172:1157-1159.
    PubMed     Abstract available


    January 2018
  157. GAYA M, Barral P, Burbage M, Aggarwal S, et al
    Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells.
    Cell. 2018;172:517-533.
    PubMed     Abstract available


    May 2017
  158. RIALDI A, Hultquist J, Jimenez-Morales D, Peralta Z, et al
    The RNA Exosome Syncs IAV-RNAPII Transcription to Promote Viral Ribogenesis and Infectivity.
    Cell. 2017;169:679-692.
    PubMed     Abstract available


    September 2016
  159. WANG A, Huen SC, Luan HH, Yu S, et al
    Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral Inflammation.
    Cell. 2016;166:1512-1525.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: